Wells Fargo
VTGN icon

Wells Fargo’s VistaGen Therapeutics VTGN Stock Holding History

Wells Fargo’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-211
Closed -$1.11K – 7510
2024
Q1 		$1.11K Buy
211
+3
+1% +$14 ﹤0.01% 6129
2023
Q4 		$1.07K Buy
208
+140
+206% +$530 ﹤0.01% 6206
2023
Q3 		$356 Buy
68
+28
+70% +$124 ﹤0.01% 6437
2023
Q2 		$75 Sell
40
-4,679
-99% -$16.4K ﹤0.01% 6942
2023
Q1 		$17.7K Buy
4,719
+1,302
+38% +$6.83K ﹤0.01% 5682
2022
Q4 		$10.6K Buy
3,417
+844
+33% +$3.18K ﹤0.01% 5532
2022
Q3 		$11K Sell
2,573
-79
-3% -$783 ﹤0.01% 5663
2022
Q2 		$70K Sell
2,652
-1,269
-32% -$44.8K ﹤0.01% 4854
2022
Q1 		$145K Sell
3,921
-2,169
-36% -$94.6K ﹤0.01% 5147
2021
Q4 		$356K Buy
6,090
+3,225
+113% +$210K ﹤0.01% 4930
2021
Q3 		$235K Buy
+2,865
New +$249K ﹤0.01% 5028
2021
Q2 		– Sell
-29
Closed -$2K – 7503
2021
Q1 		$2K Buy
29
+15
+107% +$1K ﹤0.01% 6650
2020
Q4 		$1K Hold
14
– – ﹤0.01% 6386
2020
Q3 		$0 Buy
14
+4
+40% +$83 ﹤0.01% 6973
2020
Q2 		$0 Hold
10
– – ﹤0.01% 6894
2020
Q1 		$0 Sell
10
-4,990
-100% -$91.4K ﹤0.01% 6872
2019
Q4 		$103K Hold
5,000
– – ﹤0.01% 5283
2019
Q3 		$161K Buy
5,000
+3,557
+247% +$79.3K ﹤0.01% 5088
2019
Q2 		$31K Buy
+1,443
New +$38.3K ﹤0.01% 5691

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo's VTGN Position: Q2 2024 in Review

Wells Fargo sold out of VistaGen Therapeutics (VTGN) in Q2 2024, closing a stake of 211 shares — an estimated $1.11K sold.

Wells Fargo first reported a position in VTGN in Q2 2019 and held it in 19 quarters. The position peaked at $356K in Q4 2021. 43 funds tracked by Wall St. Rank hold VTGN as of Q2 2024.

  • Wells Fargo reported no remaining VistaGen Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 211 VistaGen Therapeutics shares in Q2 2024, an estimated $1.11K.
  • Wells Fargo first reported a position in VistaGen Therapeutics in Q2 2019 and held it in 19 quarters.
  • Wells Fargo's VistaGen Therapeutics position peaked at $356K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.